Motor effects of gastrin releasing peptide (GRP) and bombesin in the canine stomach and small intestine.
Close intraarterial injections of synthetic porcine gastrin releasing peptide (GRP) or bombesin stimulated contractions in the stomach and inhibited ongoing contractile activity in the small intestine of anaesthetized dogs. Contractile activity of the circular muscle was recorded by serosal strain gauges and phasic activity when desired was elicited by local field stimulation or intraarterial motilin injections. In the stomach (corpus and antrum) following tetrodotoxin blockade of field-stimulated contractions, the contractile response to either peptide was not present, suggesting that stimulation of receptors on nerves initiated contractions in the stomach. Similarly, in the small intestine, the inhibitory response was eliminated by tetrodotoxin suggesting a neural receptor. Pre-treatment with reserpine did not alter the inhibitory response, either in the presence or absence of atropine, therefore, adrenergic inhibitory mechanisms did not appear to be involved. The concentration of bombesin producing 50% inhibition of field stimulation (ED50) was increased following treatment with the putative M1 muscarinic antagonist, pirenzipine suggesting activation of M1 cholinergic inhibitory receptors by bombesin. After blockade by atropine of field-stimulated contractions and the contractile response to intraarterial acetylcholine, the ED50 for bombesin inhibition of motilin contractions was increased. After muscarinic blockade, the residual inhibitory response of GRP/bombesin may involve activation of a neural non-cholinergic non-adrenergic inhibitory mechanism. These results suggest that GRP and bombesin act to alter motility in the dog in vivo by affecting neural activity.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001570:Benzodiazepinones / Q000494:pharmacology; D001839:Bombesin / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D019886:Gastrin-Releasing Peptide; D005765:Gastrointestinal Agents / Q000494:pharmacology; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007082:Ileum / Q000502:physiology; D007583:Jejunum / Q000502:physiology; D008297:Male; D010455:Peptides / Q000494:pharmacology*; D010890:Pirenzepine; D011706:Pyloric Antrum / Q000502:physiology; D012110:Reserpine / Q000494:pharmacology; D013270:Stomach / Q000502:physiology; D013779:Tetrodotoxin / Q000494:pharmacology
D001570:Benzodiazepinones; D005765:Gastrointestinal Agents; D010455:Peptides; D010890:Pirenzepine; D013779:Tetrodotoxin; D001285:Atropine; D019886:Gastrin-Releasing Peptide; D012110:Reserpine; D001839:Bombesin